Nippon Chemiphar To Launch 15 Generic Drugs Annually By 2012
This article was originally published in PharmAsia News
Executive SummaryNippon Chemiphar aims to launch 15 generic drugs per year by 2012, company president Kazukane Yamaguchi announced. Currently, generic drug sales account for 60 percent of Nippon Chemiphar business and the company manufactures only 40 percent of its generic products. (Click here for more - Japanese language
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.